Cargando…

Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes

BACKGROUND: Transcriptome studies are gaining momentum in genomic epidemiology, and the need to incorporate these data in multivariable models alongside other risk factors brings demands for new approaches. METHODS: Here we describe SPECTRA, an approach to derive quantitative variables that capture...

Descripción completa

Detalles Bibliográficos
Autores principales:	Griffin, Rosalie, Hanson, Heidi A., Avery, Brian J., Madsen, Michael J., Sborov, Douglas W., Camp, Nicola J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150248/ https://www.ncbi.nlm.nih.gov/pubmed/36857768 http://dx.doi.org/10.1158/1055-9965.EPI-22-0798

Ejemplares similares

Duo Shared Genomic Segment analysis identifies a genome-wide significant risk locus at 18q21.33 in myeloma pedigrees
por: Griffin Waller, Rosalie, et al.
Publicado: (2021)

Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes
por: Waller, Rosalie Griffin, et al.
Publicado: (2021)

Toxicity management strategies for next-generation novel therapeutics in multiple myeloma
por: Steinbach, Mary, et al.
Publicado: (2022)

Hospitalization at the end of life in patients with multiple myeloma
por: Abbasi, Saqib, et al.
Publicado: (2021)

The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
por: Tariq, Syed Maaz, et al.
Publicado: (2023)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma
por: Najjar, Mimi, et al.
Publicado: (2023)

Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk
por: Waller, Rosalie G., et al.
Publicado: (2018)

Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy
por: Luoma, Sini, et al.
Publicado: (2023)

Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling
por: Wang, Jin, et al.
Publicado: (2022)

Quantitative Phosphoproteomics of Proteasome Inhibition in Multiple Myeloma Cells
por: Ge, Feng, et al.
Publicado: (2010)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma
por: Ziccheddu, Bachisio, et al.
Publicado: (2021)

PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Fonseca, R., et al.
Publicado: (2022)

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile
por: Hofste op Bruinink, Davine, et al.
Publicado: (2022)

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma
por: Papadimitriou, Konstantinos, et al.
Publicado: (2020)

Metastatic Multiple Myeloma to the Skin
por: Holliday, Alex C., et al.
Publicado: (2019)

Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling
por: Banerjee, Rahul, et al.
Publicado: (2023)

Deep Response in Multiple Myeloma: A Critical Review
por: Fulciniti, Mariateresa, et al.
Publicado: (2015)

Phenotypic Detection of Clonotypic B Cells in Multiple Myeloma by Specific Immunoglobulin Ligands Reveals their Rarity in Multiple Myeloma
por: Trepel, Martin, et al.
Publicado: (2012)

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
por: Lonial, Sagar, et al.
Publicado: (2021)

Multiple Myeloma
por: Parker, D., et al.
Publicado: (1979)

Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma
por: Gil, Kellen, et al.
Publicado: (2022)

Quantitative Imaging and Radiomics in Multiple Myeloma: A Potential Opportunity?
por: Tagliafico, Alberto Stefano, et al.
Publicado: (2021)

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease
por: Garcia-Gomez, Antonio, et al.
Publicado: (2014)

Investigation of Gene Expressions of Myeloma Cells in the Bone Marrow of Multiple Myeloma Patients by Transcriptome Analysis
por: Sarıman, Melda, et al.
Publicado: (2019)

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes
por: Bustoros, Mark, et al.
Publicado: (2022)

Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes
por: Went, Molly, et al.
Publicado: (2019)

Reassessment of the relationship between M-protein decrement and survival in multiple myeloma.
por: Palmer, M., et al.
Publicado: (1989)

Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis
por: Derman, Benjamin A., et al.
Publicado: (2020)

How deep is deep enough for RNA-Seq profiling of bacterial transcriptomes?
por: Haas, Brian J, et al.
Publicado: (2012)

Editorial: Immunotherapy in Multiple Myeloma
por: Giuliani, Nicola, et al.
Publicado: (2019)

A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma
por: Paul, Barry, et al.
Publicado: (2023)

Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma
por: Pazina, Tatiana, et al.
Publicado: (2021)

Role of Galectins in Multiple Myeloma
por: Storti, Paola, et al.
Publicado: (2017)

P932: PATIENT PERSPECTIVES ON BCMA-TARGETED THERAPIES FOR MULTIPLE MYELOMA: A SURVEY CONDUCTED IN A PATIENT ADVOCACY GROUP
por: Hydren, Jay R., et al.
Publicado: (2023)

Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
por: Caers, J, et al.
Publicado: (2008)

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
por: Sawyer, Jeffrey R., et al.
Publicado: (2019)

Retrospective evaluation of the use of the International Myeloma Working Group response criteria in dogs with secretory multiple myeloma
por: Moore, A Russell, et al.
Publicado: (2020)

Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse.
por: Vanderkerken, K., et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_ot0b551ck8uk6ur21fnnuinb0d